Cervical cancer develops through persistent infection with high-risk human papilloma virus
(hrHPV) and is a leading cause of death among women worldwide and in the United States …

Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past
decade, have shown promising results in decreasing HPV infection and related diseases …

Vaccines containing novel adjuvant formulations are increasingly reaching advanced
development and licensing stages, providing new tools to fill previously unmet clinical …

Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most
common cancer and cause of cancer-related death in females worldwide. HPV also causes …

Vaccines have proven to be the most cost-efficient and reasonable way to fight and
exterminate virulent pathogens. Vaccines can be designed using a variety of platforms …

In recent decades, the improvement of traditional vaccines has meant that we have moved
from inactivated whole virus vaccines, which provoke a moderate immune response but …

When administered as standard three-dose schedules, the licensed HPV prophylactic
vaccines have demonstrated extraordinary immunogenicity and efficacy. We summarize the …

Human papilloma viruses can induce warts, condylomas, and other intraepithelial cervical
lesions that can progress to cancer. Cervical cancer is a serious problem in develo** …

Background Quadrivalent and bivalent vaccines against oncogenic human papillomavirus
(HPV) are used worldwide with different reported overall efficacies against HPV infections …